Evidence map›Paper›PMID 41868262›Full record

ArticleJournal of hepatocellular carcinoma2026

CT-Based Radiomics for Non-Invasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma.

Meilong Wu, Zhiyong Du, Ying Xiao, Yan Wang, Jintao Yang, Zhike Li, Xini Liu, Shizhong Yang, Tailai An

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meilong Wu *Division of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.ORCID 0000-0002-1336-2559
Zhiyong Du *Division of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.
Ying XiaoDepartment of Pathology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, People's Republic of China.
Yan WangDepartment of Radiology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.
Jintao YangDivision of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.
Zhike LiDivision of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.
Xini LiuDivision of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.
Shizhong YangHepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Institute for Precision Medicine, Tsinghua University, Beijing, People's Republic of China.
Tailai AnDivision of Hepatobiliary and Pancreas Surgery, Department of General Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, People's Republic of China.ORCID 0000-0003-0666-752X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: By far, non-invasive methods assessing Ki-67 are still scarce. This study was performed to evaluate the capability of radiomics based on contrast-enhanced CT in predicting expression of Ki-67 in hepatocellular carcinoma (HCC). Patients and Methods: HCC patients who underwent curative hepatectomy were included. The optimal Ki-67 cutoff value for prognostic stratification was determined using maximum selection rank statistics. The Least Absolute Selection and Shrinkage Operator (LASSO) regression analysis was used for dimension reduction and data screening to obtain radiomics features. The radiomics model, clinical model and combined model integrating radiomics features and clinical indicators for predicting Ki-67 were constructed. The predictive efficacy among the models was compared using C-index, and further verified through DeLong test, decision curves and clinical impact curves. Results: The optimal cutoff value for Ki-67 was 0.25. A total of 2553 radiomics features were obtained and after stability testing (by intraclass correlation coefficient ≥0.75) and feature selection (LASSO), four radiomics features that were highly correlated and stable with the expression of Ki-67 were included in the model construction. Multivariate analyses revealed that alpha-fetoprotein and intratumoral necrosis or radiomics features were independent predictors of Ki-67. The clinical model, radiomics model and combined model were constructed, respectively. The C-indices of Ki-67 for clinical model, radiomics model and the combined model were 0.75, 0.82 and 0.88. DeLong test, decision curves and clinical impact curves further confirmed that the inclusion of radiomics features improved the predictive efficacy of the model. Conclusion: The comprehensive model based on contrast-enhanced CT radiomics could non-invasively and effectively predict the expression of Ki-67, suggesting its value in clinical decision-making.

Indexed as

hepatocellular carcinomaKi-67prognosisradiomics

Identifiers

PMID41868262
PMCPMC13005210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.